#1 Clinical Trials Search in Europe

Prednisolone Sodium Succinate

This article examines the use of methylprednisolone sodium succinate, a corticosteroid medication, in clinical trials for various medical conditions. We’ll explore its potential benefits, applications, and ongoing research across different areas of medicine, including respiratory disorders, autoimmune diseases, and surgical interventions.

Table of Contents

What is Prednisolone Sodium Succinate?

Prednisolone Sodium Succinate is a type of medication known as a corticosteroid. Corticosteroids are synthetic drugs that mimic the effects of hormones naturally produced by the adrenal glands. They are powerful anti-inflammatory agents used to treat a wide range of conditions[1].

This medication is also known by several other names, including:

  • Methylprednisolone Sodium Succinate
  • Solu-Medrol
  • A-MethaPred
  • Medrate
  • Solu-Medrone

These alternative names may be used interchangeably in medical settings, but they all refer to the same medication[2].

Medical Uses

Prednisolone Sodium Succinate is used to treat a variety of medical conditions due to its potent anti-inflammatory and immunosuppressive properties. Some of the conditions it’s used for include:

  • COVID-19: It’s being studied for treating patients with COVID-19 pneumonia who require oxygen supplementation[1].
  • Graft-versus-Host Disease (GVHD): This is a complication that can occur after bone marrow transplantation. The medication is used to treat GVHD affecting the gastrointestinal tract[3].
  • Acute Respiratory Distress Syndrome (ARDS): This is a serious lung condition that can occur after thoracic surgery. The medication is being studied for its potential to reduce mortality in these cases[4].
  • Ocular (Eye) Conditions: It’s used in the treatment of certain eye conditions, including those related to GVHD[2].

How is it Administered?

Prednisolone Sodium Succinate can be administered in several ways, depending on the condition being treated:

  • Oral tablets: For conditions like COVID-19, it may be given as oral tablets. For example, in one study, patients took 60 mg per day for 10 days[1].
  • Intravenous (IV) injection: For conditions like GVHD, it may be given intravenously. The dose and frequency can vary based on the specific condition and patient needs[3].
  • Topical application: For eye conditions, it may be formulated as eye drops. In one study, a 0.5% concentration was used twice daily[2].

Effectiveness

The effectiveness of Prednisolone Sodium Succinate can vary depending on the condition being treated:

  • For COVID-19, research is ongoing to determine its effectiveness compared to other corticosteroids like dexamethasone[1].
  • In GVHD, it has shown promise in treating gastrointestinal symptoms[3].
  • For ARDS after thoracic surgery, early low-dose therapy is being studied for its potential to reduce postoperative mortality[4].
  • In ocular conditions, it’s being compared to other treatments like tacrolimus for effectiveness in treating dry eye symptoms related to GVHD[2].

Side Effects and Safety

Like all medications, Prednisolone Sodium Succinate can cause side effects. These can vary depending on the dosage, duration of treatment, and individual patient factors. Some potential side effects include:

  • Increased risk of infections
  • Changes in blood sugar levels
  • Changes in mood or behavior
  • Gastrointestinal issues
  • Changes in eye pressure (when used as eye drops)

It’s important to note that the safety profile can differ based on how the medication is administered. For example, when used as eye drops, the risk of systemic side effects is generally lower[2].

Ongoing Research

Prednisolone Sodium Succinate is the subject of ongoing research to better understand its effectiveness and safety in various conditions:

  • A study is comparing it to dexamethasone for treating COVID-19 patients requiring oxygen therapy[1].
  • Its use in treating GVHD of the gastrointestinal tract is being studied[3].
  • Research is ongoing to determine if early, low-dose therapy can reduce mortality in ARDS after thoracic surgery[4].
  • Its effectiveness in treating ocular GVHD is being compared to other treatments[2].

These studies aim to provide more information about the best ways to use this medication, potentially expanding its applications in medical treatment.

Condition Study Type Dosage Administration Key Outcomes Measured
Severe COVID-19 Randomized, double-blind, placebo-controlled 0.5mg/kg twice daily for 5 days Injectable Mortality rate, oxygenation index, intubation rate
Acute Respiratory Distress Syndrome (ARDS) Prospective phase II 2mg/kg Not specified Survival rate, ventilator-free days, pulmonary function
Community-acquired pneumonia Randomized, double-blind, placebo-controlled 20 mg IV Q12H for 5 days Intravenous In-hospital mortality, ICU admission, length of stay
Graft-versus-host disease Phase II Varies by study arm Intra-arterial and intravenous Response rate, survival, steroid discontinuation
Alopecia areata Randomized 15mg/kg of ideal body weight Oral Hair regrowth, safety, factors affecting response
Acute ischemic stroke Randomized, double-blind, placebo-controlled 2mg/kg (max 160mg) daily for 3 days Intravenous Mortality, intracranial hemorrhage, functional outcomes
Epilepsy in children Randomized, placebo-controlled crossover 20mg/kg (max 1000mg) for 3 days Oral Seizure frequency, adverse events, quality of life
Total knee replacement Randomized, double-blind, placebo-controlled Single dose of 125mg Intravenous Post-operative pain, range of motion, analgesic consumption

FAQ

  • What is methylprednisolone sodium succinate? Methylprednisolone sodium succinate is a corticosteroid medication used to reduce inflammation and suppress the immune system. It's being studied in clinical trials for various conditions, including respiratory disorders, autoimmune diseases, and as an adjunct therapy in surgical procedures.
  • In which medical conditions is methylprednisolone sodium succinate being studied? Clinical trials are exploring its use in conditions such as acute respiratory distress syndrome (ARDS), severe COVID-19, community-acquired pneumonia, graft-versus-host disease, alopecia areata, stroke, epilepsy, and as a pre-operative treatment in total knee replacement surgery.
  • How is methylprednisolone sodium succinate administered in these trials? The medication is administered in various ways depending on the study, including intravenously, orally, and in some cases, intra-arterially. Dosages and treatment durations vary based on the specific condition being treated and the study protocol.
  • What are some potential benefits of methylprednisolone sodium succinate? Potential benefits being studied include reduced inflammation, improved lung function in respiratory conditions, pain relief after surgery, and better outcomes in autoimmune disorders. However, the exact benefits can vary depending on the specific condition and individual patient factors.
  • Are there any risks or side effects associated with methylprednisolone sodium succinate? As with any medication, there can be risks and side effects. These may include increased blood sugar levels, changes in mood, increased risk of infections, and other steroid-related side effects. The clinical trials are designed to monitor these potential issues closely.

Ongoing Clinical Trials on Prednisolone Sodium Succinate

  • Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using Gemtuzumab Ozogamicin and a Drug Combination

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Denmark Estonia Finland Iceland Latvia +6

  • Study on Tioguanine and Drug Combination for Patients Aged 0-45 with Newly Diagnosed Acute Lymphoblastic Leukemia

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Denmark Estonia Finland France Germany +8

  • Testing inotuzumab ozogamicin and blinatumomab with drug combination for children with relapsed precursor B-cell acute lymphoblastic leukemia

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Austria Czechia Denmark Finland France Germany +5

  • Study on ABCB5+ MSCs for Recessive Dystrophic and Junctional Epidermolysis Bullosa Patients

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Croatia Denmark France Germany Greece +6

  • Study on Acute Lymphoblastic Leukemia Treatment in Children and Adolescents Using Bortezomib, Blinatumomab, and Methotrexate Combination

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Poland

Glossary

  • Methylprednisolone sodium succinate: A corticosteroid medication used to reduce inflammation and suppress the immune system, being studied in various clinical trials for different medical conditions.
  • Acute Respiratory Distress Syndrome (ARDS): A severe lung condition characterized by rapid onset of widespread inflammation in the lungs, leading to difficulty breathing and low oxygen levels in the blood.
  • Graft-versus-host disease (GVHD): A complication that can occur after a bone marrow or stem cell transplant, where the donated cells attack the recipient's body.
  • Alopecia areata: An autoimmune disorder causing hair loss in patches on the scalp or other parts of the body.
  • Community-acquired pneumonia: A type of pneumonia (lung infection) that is acquired outside of a healthcare setting, typically in the community.
  • Intra-arterial: Administration of a substance directly into an artery.
  • Placebo: A substance with no active therapeutic effect, used as a control in clinical trials to test the effectiveness of a medication.
  • Randomized controlled trial: A type of scientific experiment where participants are randomly assigned to different treatment groups to compare outcomes.
  • Sphingosine-1-phosphate (S1P): A signaling molecule involved in various cellular processes, including immune responses and maintaining the integrity of blood vessel walls.
  • Visual analogue scale: A measurement tool used to assess subjective characteristics or attitudes that cannot be directly measured, often used for pain assessment.

References

  1. https://clinicaltrials.gov/study/NCT04765371
  2. https://clinicaltrials.gov/study/NCT01977781
  3. https://clinicaltrials.gov/study/NCT02425813
  4. https://clinicaltrials.gov/study/NCT00290602